Therapeutic Effect of Different Neoadjuvant Chemotherapy on Triple Negative Breast Cancer

Objective To compare the efficacy of three different regimens of neoadjuvant chemotherapy on triple negative breast cancer(TNBC). Methods 150 patients with locally advanced TNBC diagnosed by immunohistochemistry were randomly divided into three groups with 50 cases in each group. Each group received different neoadjuvant chemotherapy regime as follows: TAC(docetaxel + epirubicin + cyclophosphamide) for group A, TC(docetaxel + cyclophosphamide) for group B,and CEF(5-fluorouracil+epirubicin + cyclophosphamide)for group C. After neoadjuvant chemotherapy, the short-term effect and adverse reactions were observed. Results The effective rate of three groups was 92.0%(TAC), 84.0%(TC) and 76.0%(CEF), respectively. The ipsilateral axillary lymph nodes lesions were decreased in all three groups after 1-5 cycles of chemotherapy regimens,and the effect of TAC was better than that of TC and CEF groups. Due to the prevention and intervention,adverse reactions of three groups were less. Conclusion The results showed that TAC neoadjuvant chemotherapy regime was more sensitive than TC and CEF to TNBC,which made c CR more accessible.